Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309245 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Peter S Chang und 18 weiteren Autor:innen. Beteiligte Einrichtung: GenomeFrontier Therapeutics TW Co., Ltd., Taipei City, Taiwan (R.O.C.). Hauptthemen laut MEDLINE: Antigens, CD19, Antigens, CD20, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GenomeFrontier Therapeutics TW Co., Ltd..
Abstract (Originalsprache)
CD19-targeted chimeric antigen receptor (CAR) T cell therapies have driven a paradigm shift in the treatment of relapsed/refractory B-cell malignancies. However, >50% of CD19-CAR-T-treated patients experience progressive disease mainly due to antigen escape and low persistence. Clinical prognosis is heavily influenced by CAR-T cell function and systemic cytokine toxicities. Furthermore, it remains a challenge to efficiently, cost-effectively, and consistently manufacture clinically relevant numbers of virally engineered CAR-T cells. Using a highly efficient piggyBac transposon-based vector, Quantum pBac ™ ( qPB ), we developed a virus-free cell-engineering system for development and production of multiplex CAR-T therapies. Here, we demonstrate in vitro and in vivo that consistent, robust and functional CD20/CD19 dual-targeted CAR-T stem cell memory (CAR-T SCM ) cells can be efficiently produced for clinical application using qPB ™. In particular, we showed that qPB ™-manufactured CAR-T cells from cancer patients expanded efficiently, rapidly eradicated tumors, and can be safely controlled via an iCasp9 suicide gene-inducing drug. Therefore, the simplicity of manufacturing multiplex CAR-T cells using the qPB ™ system has the potential to improve efficacy and broaden the accessibility of CAR-T therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GenomeFrontier Therapeutics TW Co., Ltd., Taipei City, Taiwan (R.O.C.).
- Division of Hematology, Chang Gung Medical Foundation, Linkou Branch, Taipei City, Taiwan (R.O.C.).
- Division of Hematology and Oncology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan (R.O.C.).
- Department of Medical Research, Laboratory of Good Clinical Research Center, Mackay Memorial Hospital, Tamsui District, New Taipei City, Taiwan (R.O.C.).
- Department of Medicine, Mackay Medical College, New Taipei City, Taiwan (R.O.C.).
- OBI Pharma, Inc., Taipei, Taiwan (R.O.C.).
ORCID-Profile: Peter S Chang
Förderung
- GenomeFrontier Therapeutics TW Co., Ltd.
Zitieren
APA
Chang, P. S., Chen, Y. C., Hua, W. K., Hsu, J. C., Tsai, J. C., Huang, Y. W., Kao, Y. H., Wu, P. H., Wang, P. N., Chang, Y. F., Chang, M. C., Chang, Y. C., Jian, S. L., Lai, J. S., Lai, M. T., Yang, W. C., Shen, C. N., Wen, K. K., & Wu, S. C. (2024). Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system. PLOS ONE. https://doi.org/10.1371/journal.pone.0309245
Vancouver
Chang PS, Chen YC, Hua WK, Hsu JC, Tsai JC, Huang YW, et al. Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system. PLOS ONE. 2024. doi:10.1371/journal.pone.0309245
BibTeX
@article{Chang2024,
author = {Chang, Peter S and Chen, Yi-Chun and Hua, Wei-Kai and Hsu, Jeff C and Tsai, Jui-Cheng and Huang, Yi-Wun and Kao, Yi-Hsin and Wu, Pei-Hua and Wang, Po-Nan and Chang, Yi-Fang and Chang, Ming-Chih and Chang, Yu-Cheng and Jian, Shiou-Ling and Lai, Jiann-Shiun and Lai, Ming-Tain and Yang, Wei-Cheng and Shen, Chia-Ning and Wen, Kuo-Lan Karen and Wu, Sareina Chiung-Yuan},
title = {Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309245}
}
EUVIMED